首页> 中文期刊> 《中国医药导报 》 >应用SELDI技术与MATLAB软件预测替吉奥联合榄香烯治疗消化道肿瘤敏感性的前瞻性研究

应用SELDI技术与MATLAB软件预测替吉奥联合榄香烯治疗消化道肿瘤敏感性的前瞻性研究

             

摘要

Objective: To explore the possihility of prognosis the sensibility of S-1 combined with Elemene in the treatment of digestive system cancer by SELDI technique and MATLAB software. Methods: 7 cases of patients with system cancer who treated by S-1 and Elemene effectively after surgery were collected and SELDI-TOF-MS technique was used to detect serum proteomic fingerprints. Curative effect after application of S-1 combined with Elemene from 2 weeks to 6 months were ohserved. According to the response evaluation criteria in solid tumor. 7 cases of patients were divided into stable group (4 cases, SD) and inefficacy group (3 cases, PD). The different fingerprints which had statislical significance were found by Biomarker Wizard software. The fitted curve and equation of discrepant fingerprints were obtained by MATLAB software. Results: 6 cases of protein fingerprints had significant differences between stable group and inefficacy group (P<0.05), M/Z values were 4467, 7959, 9277, 9555, 15903, 15064. Compared with stahle group M/Z values 9277. 9555 were higher and M/Z values 4467. 7959. 15903. 15064 were lower in inefficacy group. The fitted curve and equation of discrepant fingerprints assumed a linear functional relationship hy MATLAB software. Conclusion: Protein fingerprints of M/Z vaule 4467, 7959, 9277, 9555, 15903, 15064 can estimate the sensibility of S-1 combined with Elemene in the treatment of digestive system cancer%目的:借助蛋白质指纹技术及MATLAB软件探索预测替吉奥联合榄香烯治疗晚期消化道肿瘤耐药的可能性.方法:选择7例术后采用替吉奥联合榄香烯治疗有确切疗效的晚期消化道肿瘤患者,应用CM10弱阳离子芯片结合表面增强飞行时间质谱(SELDI-TOF-MS)技术于用药前检测患者血清样本的蛋白质谱,动态观察该药应用后2周至半年内的疗效,根据实体瘤近期疗效标准分为用药稳定组(SD)(4例)和无效组(PD)(3例),应用Biomarker Wizard软件得出两组间差异有统计学意义的指纹.用MATLAB软件进行多项式曲线拟合得出每个差异指纹的拟合曲线及曲线方程.结果:稳定组与无效组相比有6个蛋白质峰的差异有统计学意义(均P<0.05),蛋白质质荷比(M/Z)分别为 4467、7959、9277、9555、15903、15064,其中,与稳定组相比,无效组上调的峰M/Z为9277、9555,下调的峰M/Z为4467、7959、15903、15064.用MATLAB软件进行多项式曲线拟合得出每个差异指纹的曲线和曲线方程均呈线性函数关系.结论:替吉奥联合榄香烯治疗晚期消化道癌前检测SELDI指纹M/Z为4467、7959、9277、9555、15903、15064的蛋白质组指纹可以预测替吉奥联合榄香烯治疗晚期消化道癌的敏感性.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号